These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

830 related articles for article (PubMed ID: 12241126)

  • 1. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H; Saliba W
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ; Markham A
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment recommendations in antiarrhythmic therapy.
    Van Gelder IC; Brügemann J; Crijns HJ
    Drugs; 1998 Mar; 55(3):331-46. PubMed ID: 9530541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arrhythmias in the intensive care patient.
    Trappe HJ; Brandts B; Weismueller P
    Curr Opin Crit Care; 2003 Oct; 9(5):345-55. PubMed ID: 14508146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dofetilide: a new class III antiarrhythmic agent.
    Al-Dashti R; Sami M
    Can J Cardiol; 2001 Jan; 17(1):63-7. PubMed ID: 11173316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN; Wadhani N
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
    Singh BN
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
    Riera AR; Uchida AH; Ferreira C; Ferreira Filho C; Schapachnik E; Dubner S; Zhang L; Moffa PJ
    Cardiol J; 2008; 15(3):209-19. PubMed ID: 18651412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentially significant drug interactions of class III antiarrhythmic drugs.
    Yamreudeewong W; DeBisschop M; Martin LG; Lower DL
    Drug Saf; 2003; 26(6):421-38. PubMed ID: 12688833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
    Torp-Pedersen C; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen J; Videbaek J; Marchant B; Camm AJ
    N Engl J Med; 1999 Sep; 341(12):857-65. PubMed ID: 10486417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of atrial fibrillation with class III anti-arrhythmia agents].
    Follath F; Candinas R; Frielingsdorf J
    Herz; 1993 Feb; 18(1):20-6. PubMed ID: 8454249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.
    Advani SV; Singh BN
    Drugs; 1995 May; 49(5):664-79. PubMed ID: 7601009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter.
    Howard PA
    Ann Pharmacother; 1999 Jan; 33(1):38-47. PubMed ID: 9972384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.